# Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer

> **NCT07909122** · — · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 1 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Anti-EGFR-Based Therapy
- **DRUG:** Anti-VEGF-Based Therapy

## Key facts

- **NCT ID:** NCT07909122
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2026-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07909122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07909122, "Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07909122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
